NORTHBROOK, Ill., May 12, 2026
Astellas Pharma US announced new clinical findings showing that IZERVAY® (avacincaptad pegol intravitreal solution) significantly reduced the risk of patients with geographic atrophy (GA) progressing to loss of driving eligibility, highlighting the therapy’s growing potential to preserve functional vision in people living with advanced dry age-related macular degeneration (AMD). The results were presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and included pooled analyses from the pivotal GATHER1 and GATHER2 clinical trials.
The post hoc analysis demonstrated that patients treated with IZERVAY monthly or every other month experienced a 41% relative reduction in risk of losing driving eligibility over 24 months compared with sham-treated patients. Researchers stated that the findings suggest long-term treatment with IZERVAY may help preserve vision-dependent daily activities and improve quality of life for patients affected by the progressive retinal disease.
Geographic atrophy is an advanced stage of dry AMD characterized by irreversible retinal cell loss and progressive central vision decline. The disease affects millions of aging adults worldwide and remains one of the leading causes of severe visual impairment among elderly populations. As retinal tissue deteriorates over time, patients often lose the ability to perform routine activities such as reading, recognizing faces, and driving.
Clinical Data Shows Functional Vision Benefits
According to Astellas, the pooled analysis included patients who maintained driving eligibility at baseline, defined as best-corrected visual acuity of at least 70 ETDRS letters. By month 24, the risk of progressing to loss of driving eligibility was 12.6% among patients receiving IZERVAY compared with 20.1% among patients receiving sham treatment.
Advertisement
Investigators noted that the treatment benefits appeared to increase over time, suggesting earlier intervention with IZERVAY may offer greater long-term preservation of healthy retinal tissue. Exploratory analyses also showed that patients switching from monthly dosing to every-other-month dosing continued to demonstrate sustained clinical benefit.
The findings were supported by additional open-label extension data from the GATHER2 study, which demonstrated that IZERVAY maintained favorable safety outcomes over extended treatment periods. Researchers reported no new safety signals, no cases of retinal vasculitis or occlusive vasculitis, and no increased risk of intraocular inflammation during long-term follow-up.
Longer-term analyses also demonstrated sustained slowing of geographic atrophy lesion growth through 42 months. Patients who received earlier treatment with IZERVAY showed greater preservation of healthy retinal tissue compared with delayed treatment groups, reinforcing the potential value of earlier therapeutic intervention in GA management.
IZERVAY Expands Ophthalmology Evidence Base
Astellas executives stated that the latest findings strengthen the growing body of clinical evidence supporting IZERVAY in geographic atrophy secondary to AMD. Company leadership emphasized that preserving functional activities such as driving represents an important therapeutic goal for patients experiencing progressive vision loss.
IZERVAY is currently approved for geographic atrophy treatment in the United States, Australia, Macau, and conditionally in Japan. Astellas confirmed that it continues working with regulatory agencies globally to expand access to the therapy for additional patient populations.
The therapy previously achieved primary endpoints in both the GATHER1 and GATHER2 Phase III clinical trials, where monthly intravitreal administration significantly slowed geographic atrophy lesion growth compared with sham treatment. Across the two studies, more than 700 patients were evaluated for efficacy and safety.
Ophthalmology Innovation Gains Momentum
The latest IZERVAY findings further reinforce growing pharmaceutical investment in retinal disease therapies targeting unmet needs in aging populations. Industry analysts expect the geographic atrophy treatment market to continue expanding as biotechnology and pharmaceutical companies develop next-generation ophthalmic therapies aimed at preserving vision and delaying blindness progression.
Astellas stated that ongoing research surrounding IZERVAY reflects the company’s broader commitment to advancing innovative ophthalmology therapies capable of improving long-term visual outcomes and maintaining patient independence in progressive retinal diseases.
Source: Astellas press release
